BOTANIX PHARMACEUTICALS LTD — Director's Dealing 2023

May 21, 2023

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Botanix Pharmaceuticals Limited

ABN 70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	20 March 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	18 May 2023
No. of securities held prior to change	Vincent Peter Ippolito– direct 8,801,644 Fully Paid Ordinary Shares 12,000,000 Unlisted Options exercisable at $0.251 expiring 18 July 2023 4,000,000 Performance Rights Vincent Peter Ippolito and Karen Ann Ippolito **Trust>- trustee and beneficiary of the trust 3,000,000 Unlisted Options exercisable at $0.115 expiring 23 May 2023
Class	Fully Paid Ordinary Shares Performance Rights
Number acquired	2,000,000 Fully Paid Ordinary Shares
Number disposed	2,000,000 Performance Rights

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after the change	Vincent Peter Ippolito – direct 10,801,644 Fully Paid Ordinary Shares 12,000,000 Unlisted Options exercisable at $0.251 expiring 18 July 2023 2,000,000 Performance Rights Vincent Peter Ippolito and Karen Ann Ippolito **Trust> - trustee and beneficiary of the trust 3,000,000 Unlisted Options exercisable at $0.115 expiring 23 May 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of vested performance rights.

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Botanix Pharmaceuticals Limited

ABN 70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Matthew Callahan
Date of last notice	20 March 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Shenasaby Pty Ltd < Shenasaby A/C> - Mr Callahan is Director of the trustee and a beneficiary of the trust.
Date of change	18 May 2023
No. of securities held prior to change	Shenasaby Pty Ltd < Shenasaby A/C>- Mr Callahan is Director of the trustee and a beneficiary of the trust 73,420,124 Fully Paid Ordinary Shares 2,333,334 Performance Rights
Class	Fully Paid Ordinary Shares Performance Rights
Number acquired	1,166,667 Fully Paid Ordinary Shares
Number disposed	1,166,667 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

No. of securities held after change	Shenasaby Pty Ltd < Shenasaby A/C>- Mr Callahan is Director of the trustee and a beneficiary of the trust 74,586,791 Fully Paid Ordinary Shares 1,166,667 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of vested performance rights.

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Botanix Pharmaceuticals Limited

ABN 70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr H. William Bosch
Date of last notice	20 March 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	18 May 2023
No. of securities held prior to change	18,336,702 Fully Paid Ordinary Shares 1,000,000 Performance Rights
Class	Fully Paid Ordinary Shares Performance Rights
Number acquired	500,000 Fully Paid Ordinary Shares
Number disposed	500,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	18,836,702 Fully Paid Ordinary Shares 500,000 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of vested performance rights.

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

thispart.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A